Evgen Pharma Share Discussion Threads

[hsm12] 28/8/2019 09:44

These will have a big run to the SAH results.

[nobbygnome] 27/8/2019 17:38

👍👍

[blakeysangel] 27/8/2019 17:27

Hi everyone,
Just a little update to say I’m still on sfx01 next see my Onco on 11th September, that’s 452 days on this. Hoping for good results for SAH.

😀😀

[crapcrap] 27/8/2019 14:41

I've bought back in, hopefully,I've timed it right this time!!

[nobbygnome] 23/8/2019 20:54

Oh dear we have a troll, willywonka. In case you are not aware the next trial result is in SAH. Go and google SAH to find out what it is. They have already got a positive phase II breast cancer result so difficult to see how in the short to medium term there can be any effect of a breast cancer trial result as there isn't one ongoing!

You don't half get some muppets on these threads....

[90005nelson] 23/8/2019 20:07

"Following discussions with our clinicians and statistical advisers, we have decided to unblind the SAS trial's primary and secondary endpoint data at the same time.... This approach will maximise the commercial value of the dataset from the SAS trial."They can sell SFX-01 after the results are released, through orphan drug status.

[lovewinshatelosses] 23/8/2019 20:02

Nobody investing in this type of small cap company is unaware of the potential risk of eventual total capital losses in the event of complete failure as a worst case scenario. I am curious as to whether posts like yours ever have a material impact on the share price - but either way, if things go as holders hope, the rewards for the risks we take as early investors will likely be satisfactory. We shall see soon enough, for good or bad.

[willywonka22] 23/8/2019 19:20

This has a high risk of failure esp for breast cancer Be prepared for 70/80% drop if trials dnt go to plan

[tidy 2] 23/8/2019 15:13

Find out soon. Gla

[tidy 2] 23/8/2019 15:09

Game on. Been tipped here

[asat91] 16/8/2019 20:26

Phase II trial of SFX-01 in SAH scheduled for completion next month (September 2019)

hxxps://clinicaltrials.gov/ct2/show/record/NCT02614742

Results will shortly follow

[pdt] 15/8/2019 10:19

Another use for SFX-01 would appear to be mTOR inhibition;

"The isothiocyanate sulforaphane inhibits mTOR in an NRF2-independent manner"



One of the authors is Dinkova who is on the scientific board of Evgen. mTOR inhibition is of interest in Cancer and Neurogenerative disease.

[pdt] 08/8/2019 14:06

Interesting new article on Stroke and NRF2 from University of Florida;

Nrf2 Plays an Essential Role in Long-Term Brain Damage and Neuroprotection of Korean Red Ginseng in a Permanent Cerebral Ischemia Model.

[90005nelson] 06/8/2019 20:19

https://twitter.com/AIMBAGGER1/status/1158816066816098305?s=19

[lovewinshatelosses] 06/8/2019 19:18

Good news the other day indeed, and seems to back up those thoughts hsm12. I would have expected a more positive market reaction, but no matter - I remain long and strong, as the saying goes.

[pdt] 06/8/2019 14:49

I missed the news yesterday of further research at Kings. Clearly Kings and the British Heart Foundation (providing most of the funding) see potential in SFX-01 for Stroke.

From the release;

Professor Giovanni Mann, Professor of Vascular Physiology at King's College London and supervisor for the project, commented: "We are delighted to be collaborating again with Evgen Pharma and believe this project will build on our existing collaboration which showed great promise for SFX-01 in both stroke and potentially wider neuropsychiatric complications."

[90005nelson] 31/7/2019 21:00

It's very unusual for a company hold back in releasing primary endpoint/interim results until releasing together with the final results. They would have pulled the plug if it wasn't promising.

[hsm12] 31/7/2019 16:59

Absolutely not! No funding issues in foreseeable future. Stroke trial readout is a shot to nothing. I expect a big run up in the lead up to the results.

[lovewinshatelosses] 29/7/2019 16:30

I have a small holding here and have made a couple of little top ups along the way; I agree it does seem promising and if the results are as we all hope for, great for us shareholders one hopes and more importantly great news for the potential patients it is aimed at helping.
I am not trolling but genuinely interested in whether other holders think another small fund raise might be in the pipeline later this year? I am not looking to day trade or short EVG, just prepared to sit tight for several years if required and hold, potentially further adding, if news justifies further investment.

[pdt] 29/7/2019 12:42

hsm12 - as you say any hint of efficacy and the share price could multiply.

What I think is interesting is that any hint of efficacy could be a read across to Stroke in general where the market opportunity is x20 that of SAH. Although in SAH you are trying to mitigate a delayed ischemia there seems some evidence that sfx-01 could assist recovery post the initial event.

This is what they said in the Interims in December 2018;

"In our collaboration with Professor Giovanni E. Mann at King's BHF Centre of Research Excellence, King's College London, we have also been investigating the effects of SFX-01 in an in-vivo model of ischaemic stroke. The studies include Laser Speckle Blood Flow Imaging, a technology that shows real-time blood flow around the brain, before, during and after an experimental stroke. Whilst still ongoing, the study has shown that preconditioning with SFX-01 (i.e. three days dosing prior to stroke) improves the blood flow to the site of the stroke and this results in improved measures of functional and motor deficit. Notably, both pre-treatment and acute treatment with SFX-01 after ischaemic stroke rescued blood flow on reperfusion, suggesting that SFX-01 is protective if given before a stroke. This is promising with regard to our SAS clinical trial, where SFX-01 is administered days in advance of the ischaemia that follows the initial haemorrhage."

Certainly interesting times for Evgen.

[pdt] 26/7/2019 15:49

There does seem to be increased interest here ... expected news is still a couple of months away. I wonder if something else is brewing?

[hsm12] 26/7/2019 15:36

Probably one of the most geared biotechs in the U.K. in terms of upside. Downside always possible but any hint of efficacy is 10X.

[hsm12] 25/7/2019 15:23

Big move coming in this stock.